Objective: Assess safety and effectiveness of subretinal gene replacement therapy at 18 months post treatment.
Design: Retrospective, longitudinal study conducted at the Hospital for Sick Children in Toronto, Canada.
Participants: Patients with bi-allelic RPE65 variants, early onset retinal degeneration, and residual viable retina who underwent voretigene neparvovec r-zyl gene replacement therapy.
Objective: Biallelic RPE65 pathogenic variants may cause Leber congenital amaurosis (LCA). Voretigene neparvovec-rzyl (VN, Luxturna) is the only approved subretinal gene therapy that demonstrated benefit and safety. The eligibility criteria are vague and variable between centres.
View Article and Find Full Text PDFPurpose: To assess the risk of renal adverse events, particularly acute kidney injury (AKI), between intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Design: Meta-analysis.
Methods: A systematic literature search was conducted on Ovid Medline, Embase and the Cochrane Library for randomized controlled trials (RCTs) published from January 2005 to February 2024 involving adult patients receiving anti-VEGF intravitreal injections for agerelated macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion.
Purpose: Prior literature has suggested a reduced performance of large language models (LLMs) in non-English analyses, including Arabic and French. However, there are no current studies testing the multimodal performance of ChatGPT in French ophthalmology cases, and comparing this to the results observed in the English literature. We compared the performance of ChatGPT-4 in French and English on open-ended prompts using multimodal input data from retinal cases.
View Article and Find Full Text PDF